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Abstract 
Morbidity and mortality due to seasonal and pandemic influenza could be reduced by simpler vaccination methods that enable 
improved vaccination coverage. In this study, solid metal microneedles coated with influenza virus-like particle (VLP) vaccine were
inserted into skin for intradermal immunization. Microneedles were applied to the skin by hand and designed for simple 
administration with little or no training. Inclusion of trehalose in the coating formulation significantly increased vaccine stability 
during coating by maintaining hemagglutination activity. Mice vaccinated with stabilized microneedles developed strong antibody
responses comparable to conventional intramuscular vaccination and were fully protected against subsequent viral challenge. 
Whereas, coating microneedles with a coating solution lacking trehalose led to only partial protection against lethal viral challenge. 
Therefore, our results show that microneedles coated with trehalose-stabilized VLP vaccine can be a promising tool for improving
influenza vaccination. 
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1. Introduction 
The influenza virus is in the family of Orthomyxoviridae and RNA-containing viruses with immunogenic surface 
proteins such as hemagglutinin (HA) and neuraminidase (NA) (1). Influenza viruses have been a critical cause of death 
and hospitalization, and their global impact on public health has received increased attention due to the recent 
emergence of the new swine H1N1 virus (2).  
The spread of influenza viruses can be effectively prevented by vaccination (3). In contrast to conventional 
vaccination by injection with a hypodermic needle by a trained medical expert, vaccination using microneedles has 
recently been investigated as a simple method of vaccine administration that targets vaccine antigen delivery to the skin 
(4). Microneedles have been designed in various ways, including formulation as a patch coated with vaccine that can be 
applied to the skin by personnel with minimal training or possibly by patients themselves. In addition, immunization 
via the skin is attractive in part because the epidermis and dermis have abundant antigen-presenting cells such as 
Langerhans and dermal dendritic cells (5). Previously, microneedles have been studied for influenza vaccination using 
inactivated virus antigens using coated microneedle patches (6-11), as well as hollow microneedles for injection (12, 
13). These studies showed that influenza vaccination in this way induced strong humoral and cellular immune 
responses.   
Virus-like particle (VLP) vaccines have been a major advance in subunit immunogen research and derived attention 
due to their expected improvements in safety and cellular immunogenicity compared to inactivated virus vaccines (14). 
Influenza VLPs have been widely used for influenza vaccination and shown promise for effective vaccination (15).  
                                                    
1 *To whom correspondence should be addressed. 
E-mail: rcompan@emory.edu (R.W.C), 
skang2@emory.edu (S.M.K.), prausnitz@gatech.edu (M.R.P.)1
© 2010 Published by Elsevier Ltd.
3rd  Vaccine Global Congress, Singapore 2009 
18  Yeu-Chun Kim et al. / Procedia in Vaccinology 2 (2010) 17–21
In this study, we evaluated the use of microneedle patches coated with VLPs as a simple method of influenza 
vaccination. We further examined the role of trehalose to stabilize the influenza VLP vaccines during microneedle 
coating and thereby retain their immunogenicity.  
2. Materials and methods 
2.1. Preparation of influenza VLPs and coated microneedles 
VLP vaccine containing influenza M1 and HA (A/PR/8/34) was prepared as described in our previous study (15). 
Stainless steel microneedles were fabricated using laser cutting and electro-polishing, as described before (6). To apply 
a vaccine coating, microneedles were dipped six times at room temperature into coating solution using a dip-coating 
device and air dried. The standard coating solution was composed of 1% (w/v) carboxymethylcellulose sodium salt 
(Carbo-Mer), 0.5% (w/v) Lutrol F-68 NF (BASF), and 2 mg/ml VLP vaccine in phosphate buffered saline (PBS). In 
some cases, 15% (w/v) trehalose (Sigma Aldrich) was added.  
2.2. Stability of influenza VLPs according to drying time 
A 1 ȝL droplet of coating solution either with or without trehalose was mixed with 1 ȝL of VLP vaccine on a 3 
mm × 3 mm piece of the same stainless steel used to make microneedles. After drying in air at room temperature for 
different drying times, the coating was dissolved from the metal piece in 100 ȝL of PBS for 12 h. Coating on these 
metal pieces produced similar antigen stability to coating stainless steel microneedles (data not shown), which suggests 
that using these metal pieces is a suitable model system.  To determine hemagglutination (HA) titers as a measurement 
of stability of VLPs containing influenza hemagglutinin after coating, VLP vaccine dissolved from the metal pieces 
was serially diluted in 100 ȝL of PBS deficient in Mg2+ and Ca2+, mixed with an equal volume of a fresh 0.5% 
suspension of chicken red blood cells (Lampire), and incubated for 1 h at 25°C. The titers were determined as the 
endpoint dilutions inhibiting the precipitation of red blood cells (16) . 
2.3. Immunization using microneedles 
BALB/c mice (Charles River) were anesthetized intramuscularly with 110 mg/kg ketamine (Abbott Laboratories) 
mixed with 11 mg/kg xylaxine (Phoenix Scientific). The skin on the back of the mouse was exposed by removing hair 
with depilatory cream (Nair), washed with 70% ethanol, and dried with a hair dryer. An in-plane, five-needle array of 
microneedles coated with 1 ȝg of influenza VLP vaccine formulated either with or without trehalose was manually 
inserted into the skin and left for 10 min to dissolve the vaccine coating in the skin. The vaccine dose coated on 
microneedles was measured by a BCA protein assay kit (Pierce). As a positive control, 1 ȝg of influenza VLP vaccine 
formulated either with or without trehalose was dissolved from a microneedle array in 100 ȝl PBS and injected 
intramuscularly in the upper quadriceps muscles of mice. Naïve (i.e., negative control) mice received no treatment.  
2.4. Antibody responses and viral challenge infection after immunization 
Influenza virus-specific antibody (IgG) was measured by enzyme-linked immunosorbent assay (ELISA) (15). Data 
are presented as optical densities read at 450 nm. For virus challenge, isoflurane-anesthetized mice were intranasally 
infected with the mouse-adapted A/PR8 virus (20 LD50) five weeks after vaccination. Mice were observed daily to 
monitor changes in body weight and to record mortality. All animal studies were approved by the Emory University 
Institutional Animal Care and Use Committee.  
2.5. Statistical Analysis 
Every assay was measured using at least three samples, from which the arithmetic mean and standard error of the 
mean were calculated. A two-tailed Student’s t-test (Į=0.05) was performed when comparing two different conditions. 
In all cases, a value p<0.05 was considered statistically significant. 
3. Results and discussion 
3.1. Effect of trehalose on the kinetics of HA activity loss by VLPs coated onto microneedles 
Previous studies have shown that coating of inactivated whole influenza vaccines onto microneedles can damage 
their stability (6). Because VLPs contain hemagglutinin as a major antigenic component, we measured HA activity to 
assess vaccine stability during the drying process of influenza VLP vaccine. Because previous studies showed that the 
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addition of trehalose to the coating formulation can help stabilize other influenza vaccines (6), we also studied the 
effect of trehalose on the kinetics of VLP vaccine activity during a 1-h short-term study and 2-week long-term study 
(Fig. 1)
During the short-term study, HA activity of the VLP vaccine dropped to approximately 60% within 20 min 
independent of the presence of trehalose in the coating formulation (Fig. 1A). Without trehalose, HA activity continued 
to drop, such that almost all HA activity was lost by the 30 min time point. However, with trehalose in the formulation, 
HA activity remained stable from the 20 min time point until the 1 h time point. This indicates that there were two 
phases of HA activity loss during the drying process. While trehalose did not protect the vaccine during the first phase, 
it did provide significant protection during the second phase and thereby retained HA activity at 60%.  
During the long-term study, almost all HA activity was lost before the first measurement at 1 day for VLP vaccine 
lacking trehalose stabilization (Fig.1B). In contrast, the presence of trehalose helped the VLP vaccine to retain 60% 
HA activity until 3 days. There was then a gradual decrease in HA activity to 25% during the period up to 7 days. After 
day 7, there was no significant drop in HA activity through day 14. This suggests that there is a third phase of HA 
stability loss over a time scale of days, for which trehalose provided a role in maintaining HA activity.  
Overall, we found that microneedle coating of VLPs caused a rapid loss in vaccine stability as determined by 
HA activity. The addition of trehalose disaccharide sugar to the coating formulation significantly stabilized VLPs 
during microneedle coating and initial storage. However, the VLPs slowly lost HA activity within 1 week. Therefore, 
additional studies are required to further stabilize the VLPs and thereby maintain HA activity during an extended 
period of storage.  
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Figure 1.  Effect of trehalose on the kinetics of HA activity loss of influenza VLPs coated onto microneedles. VLPs were coated (z) without and 
(V) with 15% trehalose present in the coating formulation. HA activity was measured at different time points to assess the stability of influenza 
VLPs. (A) Short-term and (B) long-term kinetics of HA activity loss (SCS: standard coating solution, T: trehalose). 
3.2. Induction of antibody response and protection against viral challenge after vaccination 
To validate in vitro findings of vaccine stability, we next immunized mice to evaluate immunogenicity after 
immunization using microneedles with and without trehalose. Groups of mice were microneedle-immunized with a 
single 1 µg dose of influenza VLP vaccine in the skin after coating the vaccine onto microneedles in the absence (MN, 
n=6) or presence of trehalose (MN+T, n=6). In order to compare with the conventional intramuscular route of 
immunization, mice were immunized with influenza VLP vaccine that was dissolved from coated microneedles in the 
absence (IM, n=6) or presence of trehalose (IM+T, n=6) using intramuscular injection. A naive control group did not 
receive immunization (n= 6). 
Serum samples taken at 2 and 4 weeks after immunization were used to determine A/PR8 virus-specific total IgG 
antibodies. As shown in Fig. 2A, microneedle immunizations (MN, MN+T) induced lower levels of IgG antibodies 
than those by the stabilized intramuscular injection (IM+T) but higher than those by the unstabilized intramuscular 
injection (IM) at week 2. However, levels of IgG in the stabilized microneedle group (MN+T) caught up those from the 
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corresponding intramuscular group  (IM+T) at week 4, which was significantly higher than those induced by 
unstabilized influenza VLP vaccination by either route (MN, IM).  
Five weeks after immunization, groups of mice including the naïve mice were challenged with a lethal dose of 
influenza virus infection. All of the naïve mice lost over 20% of body weight by day 5 and died (survival rate=0%). In 
contrast, both of the microneedles groups (MN, MN+T) and the stabilized intramuscular group of mice (IM+T) were 
completely protected from lethal virus challenge (survival rate=100%). The stabilized microneedle group (MN+T) lost 
less body weight than the other two groups (MN, IM+T) which showed 5-7% loss in body weights (Fig. 2B). However, 
only 67% of mice in the unstabilized intramuscular group (IM) survived lethal challenge infection and lost body weight 
up to 15%, which indicates serious illness (Fig. 2B). 
From these results, we found that vaccination using trehalose-stabilized VLP vaccine (MN+T) induced a robust 
antibody response that conferred complete protection from challenge similar to intramuscular vaccination using the 
same formulation (IM+T). Microneedle vaccination without trehalose stabilization (MN) yielded an inferior antibody 
response compared to the trehalose-stabilized formulation (MN+T). Importantly, it is worth to note that intramuscular 
injection of VLPs lacking trehalose stabilization (IM) were even less protective than microneedle vaccination (MN).   
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Figure 2. Induction of antibody response and protection against lethal challenge after vaccination. (A) Total serum antibody responses specific to 
influenza virus (IgG) measured 2 and 4 weeks after immunization with either microneedles coated with VLP vaccine or intramuscular injection with 
the same VLP vaccine (+: p<0.05 compared to MN, ^: p<0.05 compared to MN+T, *: p<0.05 compared to IM). (B) Body weight change of 
immunized mice after lethal challenge infection. (MN: microneedles without trehalose, MN+T: microneedles with trehalose,  IM: intramuscular 
injection of reconstituted vaccine without trehalose, IM+T: intramuscular injection of reconstituted vaccine with trehalose, Naive: no treatment.)
4. Conclusion 
Microneedles used in this study offer the opportunity to simplify vaccination through the use of a patch that could be 
applied by minimally trained personnel or possibly through self administration. In vitro vaccine stability and in vivo 
immunogenicity studies showed that microneedle vaccination using influenza VLPs that were stabilized with trehalose 
induced protective immunity similar to intramuscular injection. We also found that VLPs coated without trehalose in 
the formulation were more immunogenic when administered using microneedles compared to intramuscular injection, 
indicating that the microneedle route of administration in the skin could be more effective in inducing protective 
immunity in this situation. Our results thus demonstrate that microneedles coated with trehalose-stabilized VLP vaccine 
can be a promising tool for improving influenza vaccination. 
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